Sanofi secures exclusive rights to develop plozasiran in Greater China, enhancing treatment options for hypertriglyceridemia ...

Arrowhead Pharmaceuticals’ subsidiary Visirna Therapeutics has entered an asset purchase agreement with Sanofi for the rights ...

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced the signing of an asset purchase agreement between Sanofi and Visirna Therapeutics, a majority-owned subsidiary of Arrowhead created to ...

The deal with Arrowhead's Visirna Therapeutics subsidiary – which also includes $265 million in milestones tied to potential ...

Arrowhead Pharmaceuticals strikes a $130M+ deal with Sanofi for plozasiran in Greater China, targeting high triglyceride ...

US RNA interference (RNAi)specialist Arrowhead Pharmaceuticals (Nasdaq: ARWR) today announced that its majority-owned subsidiary Visirna Therapeutics has signed an asset purchase agreement with France ...

Sanofi is handing over $130 million upfront for the China rights to Arrowhead Pharmaceuticals’ rare metabolic disease ...

Sanofi will acquire rights to develop and commercialize the drug for $130 million upfront, with Visirna eligible for up to $265 million in milestone payments.

Fully cell-free process aims to democratize personalized cancer therapeutics with shorter turnaround and negligible bioburden and endotoxin risks.

By Kelly Cloonan Century Therapeutics plans to cut 51% of its employees as it looks to focus on programs with the highest potential for value.

Plus Therapeutics plans to present additional data from the completed single-dose trial at the upcoming SNO/ASCO CNS Metastases Conference in August and will request an End of Phase 1 meeting with ...

Investing.com -- MiNK Therapeutics, Inc. (NASDAQ: INKT) stock soared 200% after the company announced a complete remission in a patient with metastatic testicular cancer following treatment with ...